A5005937823- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Radiomics and Machine Learning in Medical Imaging
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Brain Metastases and Treatment
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
- Global Cancer Incidence and Screening
- Neuroendocrine Tumor Research Advances
- Cancer Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Esophageal Cancer Research and Treatment
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Women's cancer prevention and management
- Chemotherapy-induced cardiotoxicity and mitigation
- Medical Imaging and Pathology Studies
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
D’Or Institute for Research and Education
2020-2025
Nizam's Institute of Medical Sciences
2008-2023
Jeroen Bosch Ziekenhuis
2008-2023
Heidelberg University
2008-2023
University Hospital Heidelberg
2008-2023
Instituto Nacional do Câncer
2004-2022
Instituto Superior de Educação do Rio de Janeiro
2016-2021
Hospital São Vicente
2021
Seoul National University Hospital
2021
Centro Brasileiro de Estudos em Dermatologia
2020
Purpose Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies pemetrexed platinum compounds have also shown activity in this setting. Patients and Methods This noninferiority, phase III, randomized study compared the overall survival between arms using fixed margin method (hazard ratio [HR] < 1.176) 1,725 chemotherapy-naive patients with stage IIIB or IV NSCLC an Eastern Cooperative Oncology Group...
Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies pemetrexed platinum compounds have also shown activity in this setting.
To compare single-agent pemetrexed (P) versus the combination of carboplatin and (CP) in first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2.In a multicenter phase III randomized trial, NSCLC, ECOG PS 2, any histology at first later amended to nonsquamous only, no prior chemotherapy, adequate organ function were randomly assigned P alone (500 mg/m(2)) or CP (area under curve 5 500 mg/m(2),...
Purpose This report describes the quality of life (QOL) findings a randomized placebo controlled study erlotinib, an epidermal growth factor receptor inhibitor, in patients with non–small-cell lung cancer (NSCLC). Patients and Methods double-blind phase III trial randomly assigned 731 NSCLC who had progressed after prior chemotherapy to erlotinib 150 mg daily or placebo, survival as primary outcome. QOL was assessed by European Organisation for Research Treatment Cancer QLQ-C30 module...
PURPOSE This phase II/III double-blind study assessed efficacy and safety of cediranib with standard chemotherapy as initial therapy for advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Paclitaxel (200 mg/m(2)) carboplatin (area under the serum concentration-time curve 6) were given every 3 weeks, daily oral or placebo at 30 mg (first 45 patients received mg). Progression-free survival (PFS) was primary outcome II interim analysis; III would proceed if hazard ratio (HR) PFS...
Abstract Crizotinib is a multi-tyrosine kinase inhibitor (mTKI) with efficacy in treating c-ROS oncogene 1-positive non-small cell lung cancer (NSCLC). The association between this TKI and the development of renal cysts well established, although data on formation aseptic abscesses scarce. We report case patient ROS1-positive NSCLC treated crizotinib who developed multiple extrarenal associated quick resolution these lesions after discontinuation therapy. aim to rare presentation...
New cases of the novel coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome 2 (SARS-CoV-2), continue to rise worldwide following declaration a pandemic by World Health Organization (WHO). The current has completely altered workflow health services worldwide. However, even during this critical period, patients with other diseases, like cancer, need be properly treated. A few reports have shown that mortality due SARS-CoV-2 is higher in elderly and those active...
7506 Background: No standard of care exists for patients with advanced NSCLC and PS 2 clinical practice ranges from supportive to combination chemotherapy. Methods: In a Brazilian multicenter phase III randomized trial, patients, any histology at first, amended non-squamous only, 2, no prior chemotherapy, adequate organ function, were P alone (500 mg/m2) or CP (AUC 5 + same P) administered every 3 weeks 4 cycles. Stratification factors included stage (IIIB vs. IV); age (≥70 <70); weight...
Abstract Background The aim of this study was to carry out a descriptive analysis the somatic genetic profile and co‐occurring mutations non‐small cell lung cancer (NSCLC) samples from patients tested with comprehensive genomic profiling (CGP). Methods This retrospective cross‐sectional diagnosed NSCLC 2013 2018 in Brazil whose were submitted CGP (FoundationOne or FoundationACT) using either tumor circulating DNA (ctDNA) plasma. Results We recovered 513 results patients, 457 (89.1%) which...
Outcomes data on Non-Small Cell Lung Cancer (NSCLC) are scarce with regard to the private health care in Brazil. The aim of this study was describe characteristics, treatments performed, and survival patients NSCLC a Brazilian oncologic institution.Medical charts from treated between 1998 2010 were reviewed, transferred clinical research form. Long-term follow-up estimates enabled through active surveillance.Five hundred sixty-six included, median age 65 years. Most diagnosed advanced stages...
PURPOSE There is a paucity of consistent data concerning genetic mutations in Brazilian patients with lung cancer. The aim this study was to retrospectively analyze epidermal growth factor receptor (EGFR) detected real-world scenario using large cohort non–small-cell cancer (NSCLC). MATERIALS AND METHODS This cross-sectional, observational, descriptive on the basis database EGFR molecular analysis from tumor samples confirmatory histopathological diagnosis primary Specimens were collected...
7511 Background: In NCIC CTG study BR24, CED 30 mg/d + CP increased objective response rate (RR) and progression-free survival (PFS), but there were concerns regarding toxicity in some pts. BR29 tested a lower dose of 20 limiting accrual to pts without significant weight loss/hypoalbuminemia. Methods: Consenting, eligible adult with advanced incurable NSCLC any histology randomized receive or PLA up 6 cycles C (AUC = 6) P (200 mg/m 2 ); non-progressing continued CED/PLA after until...
Two classes of epidermal growth factor receptor (EGFR) inhibitors are currently available for clinical use: tyrosine-kinase (TKIs) and monoclonal antibodies. The introduction pharmacological agents that able to inhibit EGFR represents an important step in the management patients with advanced non-small cell lung cancer (NSCLC), leading cause death worldwide. use has not only led meaningful therapeutic gains patients, but also expanded our knowledge about disease itself, as it is now...
Of newly diagnosed patients with non-small-cell lung cancer (NSCLC), stage III accounts for 30%. Most are treated concurrent chemoradiation therapy, but the addition of consolidation chemotherapy (CC) is debatable. We examined effect CC in Brazilian NSCLC routine clinical practice.We retrospectively collected data from five different institutions who had and were therapy followed or not by CC. Eligible age 18 years older must have been cisplatin-carboplatin plus etoposide, paclitaxel,...
Adjuvant chemotherapy is recommended for most patients submitted to resection due non-small cell lung cancer (NSCLC) staged as II or IIIA. However, although various regimens that include cisplatin have been used in phase III trials, the best choice remains unclear. The objective of this study was describe experience Instituto Nacional do Câncer (INCA, Brazilian National Cancer Institute), located city Rio de Janeiro, Brazil, with use cisplatin-etoposide combination such patients, a special...